Your session is about to expire
← Back to Search
Loop Diuretic
The Use of Furosemide in Patients on Dialysis
Phase 4
Waitlist Available
Led By Marc B Goldstein, MD
Research Sponsored by Unity Health Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Inclusion Criteria:all patients taking Furosemide -
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
All Individual Drugs Already Approved
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Approved for 10 Other Conditions
Summary
This trial aims to determine if dialysis patients still benefit from taking Furosemide, a drug that helps remove extra salt and water from the body. By comparing urine samples before and after taking the drug, researchers will see if it helps control blood pressure and reduce heart risks. The results will guide doctors on whether to continue prescribing Furosemide to these patients. Furosemide is a diuretic commonly used to treat fluid retention and swelling caused by various medical conditions, including chronic kidney disease and heart failure.
Eligible Conditions
- Kidney Failure
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
24 hour urine sodium and water excretion
Secondary study objectives
Interdialytic weight gain
Other study objectives
The patients' BP on and off the drug will be compared
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Administration of furosemideExperimental Treatment1 Intervention
The patient will receive furosemide 120 mgms daily
Group II: Withdrawal of FurosemideActive Control1 Intervention
The patient's Furosemide will be withdrawn
Find a Location
Who is running the clinical trial?
Unity Health TorontoLead Sponsor
559 Previous Clinical Trials
455,395 Total Patients Enrolled
1 Trials studying Kidney Failure
215 Patients Enrolled for Kidney Failure
Marc B Goldstein, MDPrincipal InvestigatorUnity Health Toronto